Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis

BACKGROUND: Psoriasis is a chronic inflammatory skin disease, affecting about 0.6% of the Chinese population. Many patients are not well controlled by conventional treatments, thus there is need for new treatment regimens. In this study, we assessed the efficacy and safety of secukinumab in Chinese...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Chin Med J (Engl)
Autors principals: Cai, Lin, Zhang, Jian-Zhong, Yao, Xu, Gu, Jun, Liu, Quan-Zhong, Zheng, Min, Zhang, Shi-Fa, Xu, Jin-Hua, Li, Cheng-Xin, Cheng, Hao, Guo, Qing, Pan, Wei-Li, Li, Shen-Qiu, Li, Ruo-Yu, Guo, Zai-Pei, Song, Zhi-Qi, Li, Shan-Shan, Dong, Xiu-Qin, Wang, Linda, Fu, Rong, Regnault, Pascaline, Charef, Pascal, Mazur, Rafal, Patekar, Manmath
Format: Artigo
Idioma:Inglês
Publicat: Lippincott Williams & Wilkins 2020
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7647502/
https://ncbi.nlm.nih.gov/pubmed/33060370
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CM9.0000000000001163
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars